Mirtazapine Drug MarketSize, Share & Industry Analysis, 2026-2034By Drug TypeBy Dosage FormBy ApplicationBy Distribution ChannelBy End User

Mirtazapine is a tetracyclic antidepressant sold as immediate-release tablets and orally disintegrating tablets, prescribed primarily for major depressive disorder and, off-label, for generalized anxiety and the sleep and appetite disturbances that accompany depression. It is manufactured almost entirely as a generic small-molecule drug today, dispensed through hospital, retail and increasingly online pharmacy channels to adult and geriatric patients under a physician's prescription. Buyers of this report are generic drug manufacturers, pharmacy benefit managers and distributors tracking volume, pricing and channel shifts in an established, off-patent CNS therapy.

Between 2025 and 2034 the global mirtazapine drug market moves from USD 1.894 billion to USD 2.897 billion, compounding at 4.85% a year. Fifteen years are covered in all, taking in USD 1.52 billion in 2020, USD 1.812 billion in 2024, USD 1.983 billion in 2026 and USD 2.415 billion in 2030.

On the drug type axis, growth rates run from 1.19% for Branded up to 5.2% for Generic. Generic carries the volume: USD 1.705 billion and 90% of revenue in 2025, USD 2.686 billion and 92.7% in 2034. Share moves toward Generic and away from Branded, though no line shrinks in revenue terms.

The dosage form split puts Tablets first, at USD 1.705 billion and 90% of revenue in 2025, rising to USD 2.491 billion and 86% in 2034. Orally Disintegrating Tablets grows faster at 8.87% against 4.3%, moving from 10% of revenue to 14% by 2034. It cuts the same total as the drug type axis from a different commercial angle, so revenue does not add across the two.

The regional order runs from North America at 34% of 2025 revenue down to Middle East and Africa at 5%. North America is worth USD 0.644 billion in 2025 and USD 0.898 billion in 2034; Europe, second at 28%, moves from USD 0.53 billion to USD 0.753 billion. Asia Pacific and Latin America gain share across the period, so growth is not distributed evenly between regions.

The 2025 total is arrived at by triangulating published aggregates against category proxies, not by an independent count. Segment, regional and country splits are estimated on the same basis, which bounds the precision of the figures above. Coverage runs to five regions, two drug type lines and five segmentation axes across a fifteen-year window.

• A forecast-period rate of 4.85% takes the market from USD 1.894 billion in 2025 to USD 2.897 billion in 2034, against 4.5% recorded over the 2020-2025 historical period.
• 90% of 2025 revenue sits in Generic (USD 1.705 billion) and it remains the largest drug type line in 2034 at USD 2.686 billion and 92.7%.
• The bull case puts 2034 revenue at USD 3.071 billion and the bear case at USD 2.723 billion, either side of the USD 2.897 billion base case, each with its own stated assumption in the full report.
• North America holds 34% of global revenue in 2025 at USD 0.644 billion, the largest of the five regions tracked, and reaches USD 0.898 billion by 2034.
• 84.9% of North America's base-year revenue comes from the United States alone: USD 0.547 billion in 2025, rising to USD 0.763 billion by 2034, which is why it is that region's worked example.
• The study covers 2020 through 2034 with 2025 as the base year, reporting five regions and five segmentation axes separately, with revenue, share and a growth rate for every line in each year.

Three things move over 2026-2034, and they are worth separating: the drug type mix, the regional balance, and the 4.85% compounding underneath both.

All three are changes in mix, not in direction: nothing contracts, and the movement is in which lines and regions absorb the new revenue.

Generic outpaces Branded. Generic grows at 5.2% across 2026-2034 against 1.19% for Branded, the widest spread on the drug type axis. Over the forecast period that moves Generic from 90% of revenue to 92.7%, and Branded from 10% to 7.3%. Revenue rises on both sides; USD 1.705 billion to USD 2.686 billion and USD 0.189 billion to USD 0.211 billion respectively, so this is a change in composition, not a contraction, and one forecast window is long enough for it to matter.

The regional balance moves. Asia Pacific moves from 26% of revenue in 2025 to 30% in 2034, worth USD 0.492 billion rising to USD 0.869 billion; Latin America moves from 7% of revenue in 2025 to 8% in 2034, worth USD 0.133 billion rising to USD 0.232 billion. Against that, North America at 34% moving to 31%, Europe at 28% moving to 26%, Middle East and Africa at 5% moving to 5%, a fall in share, not in revenue. Revenue added in this market is therefore concentrating geographically instead of spreading evenly, and a participant weighted toward a share-losing region grows more slowly than the market even while its own revenue climbs.

The series never breaks trajectory. Fifteen years of revenue run USD 1.52 billion in 2020, USD 1.812 billion in 2024, USD 1.894 billion in 2025, USD 1.983 billion in 2026, USD 2.415 billion in 2030 and USD 2.897 billion in 2034. No year breaks the trajectory, and the 4.85% forecast rate compares with 4.5% recorded over 2020-2025, a continuation, not an inflection. That moves the planning question away from timing a turn and onto the drug type and regional mixes, where the actual movement is.

Generic carries the market's growth rate

Three sources account for the growth to 2034: 4.85% compounding across the base, share moving toward the faster drug type lines, and above-market expansion in the leading regions.

Downside case: USD 2.723 billion by 2034, against USD 2.897 billion in the base case

Where the forecast could be beaten

The total depends on a single line

34% of the global mirtazapine drug market sits in North America in 2025, worth USD 0.644 billion on the way to USD 0.898 billion by 2034. By revenue it sits first across the study, and the ranking does not change between 2025 and 2034.

Its share moves to 31% by 2034, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.

The drug type mix reported at global level applies here, with Generic the largest line at 90% of 2025 revenue and Generic the fastest-growing at 5.2%. The full report breaks North America out along every axis and by country.

The largest single market in North America is the United States, at USD 0.547 billion in 2025 and USD 0.763 billion in 2034. 84.9% of the region in 2025 means the regional figures are, in practice, a view of this market with others attached. The region itself runs USD 0.644 billion to USD 0.898 billion over the same period, and this is the market carrying the country-level detail in the full report.

Demand in the United States follows the drug type mix reported at global level: Generic is the largest line at 90% of 2025 revenue, moving to 92.7% by 2034, while Generic grows fastest at 5.2% and takes its share from 90% to 92.7%. With 84.9% of North America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Per-drug type revenue for the United States appears on its own in the full report.

In the United States, mirtazapine is regulated as a prescription drug under the Federal Food, Drug, and Cosmetic Act, with the Food and Drug Administration overseeing its approval, manufacturing, and marketing. A manufacturer seeking to market a mirtazapine product must file either a New Drug Application or, once the branded product has lost exclusivity, an Abbreviated New Drug Application demonstrating bioequivalence to the reference listed drug. Facilities must conform to current Good Manufacturing Practice standards, and the approved labeling, including the boxed warning language required for antidepressants, must accompany every package. Because mirtazapine is not scheduled as a controlled substance, distribution follows standard pharmacy dispensing rules, not the additional recordkeeping required for scheduled drugs.

The United States does not have a competitive structure of its own; position here is position on the drug type axis reported above. Generic is both the largest line, at 90% of 2025 revenue, and the fastest-growing at 5.2%. Country-level positioning and shares for each of these companies are part of the full report, not of this summary.

Canada is sized at USD 0.097 billion in 2025, rising to USD 0.135 billion by 2034; 5.1% of global revenue and 15.1% of North America. It is reported separately from the United States across every segmentation axis in the full report.

USD 0.53 billion of 2025 revenue is generated in Europe, 28% of the global mirtazapine drug market and reaches USD 0.753 billion by 2034. By revenue it sits second across the study, and the ranking does not change between 2025 and 2034.

26% of global revenue sits here in 2034, below the 2025 level, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

Within the region the drug type split tracks the global one; 90% of 2025 revenue in Generic, fastest growth of 5.2% in Generic. The full report breaks Europe out along every axis and by country.

USD 0.159 billion of Europe's 2025 revenue is generated in Germany, the region's largest market, reaching USD 0.226 billion by 2034. Its 30% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. Regional revenue of USD 0.53 billion in 2025 and USD 0.753 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

The drug type pattern in Germany is the global one: 90% of 2025 revenue in Generic, 92.7% by 2034, against 5.2% growth in Generic taking it from 90% to 92.7%. Because the country carries 30% of Europe, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. The full report reports Germany by drug type separately.

In Germany, mirtazapine is classified as a prescription-only medicine under the Arzneimittelgesetz, the national law implementing European Union pharmaceutical directives. Marketing authorization is granted through the Bundesinstitut für Arzneimittel und Medizinprodukte, either directly or through the mutual recognition procedures used across the European Union. A supplier must demonstrate quality, safety, and efficacy, manufacture under European Good Manufacturing Practice standards, and supply a package leaflet and physician information sheet that meet European labelling requirements. Pharmacies may dispense the product only against a valid prescription, and pharmacovigilance obligations continue after approval, requiring the marketing authorization holder to report adverse reactions to German and European authorities.

Germany does not have a competitive structure of its own; position here is position on the drug type axis reported above. One line leads on both counts here: Generic holds 90% of 2025 revenue and compounds fastest at 5.2%. The commercial size of that position is USD 0.53 billion in 2025 and USD 0.753 billion by 2034, 28% of the global total in the base year.

Within Europe, the United Kingdom accounts for 25.1% of regional revenue and 7% of the global total, worth USD 0.133 billion in 2025 and USD 0.188 billion by 2034.

Within Europe, France accounts for 20% of regional revenue and 5.6% of the global total, worth USD 0.106 billion in 2025 and USD 0.151 billion by 2034.

In Asia Pacific, 26% of global revenue puts 2025 at USD 0.492 billion and reaches USD 0.869 billion by 2034. It is a leading region on this axis, third by revenue throughout the period.

Its share rises to 30% over the forecast period, so the region grows faster than the market's 4.85% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

Segment composition follows the global pattern: Generic largest at 90% of 2025 revenue, Generic fastest at 5.2%. Per-axis and per-country detail for Asia Pacific sits in the full report.

USD 0.172 billion of Asia Pacific's 2025 revenue is generated in China, the region's largest market, reaching USD 0.304 billion by 2034. Its 35% of base-year regional revenue leads the region, though enough sits elsewhere that Asia Pacific is not a proxy for it. Set against USD 0.492 billion and USD 0.869 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

The drug type pattern in China is the global one: 90% of 2025 revenue in Generic, 92.7% by 2034, against 5.2% growth in Generic taking it from 90% to 92.7%. With 35% of Asia Pacific concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The full report reports China by drug type separately.

In China, mirtazapine falls under the oversight of the National Medical Products Administration, which governs drug registration, manufacturing licensing, and post-market surveillance. A supplier must obtain a drug registration certificate confirming that the product meets the standards set out in the Chinese Pharmacopoeia, and manufacturing sites must hold Good Manufacturing Practice certification issued under national rules. Because mirtazapine is dispensed only against a physician's prescription, packaging and inserts must carry Chinese-language labelling that matches the approved instructions, including dosage guidance and safety warnings. Imported product also requires an import drug license, and the registration holder remains responsible for reporting adverse events to the Administration once the product reaches the market.

China does not have a competitive structure of its own; position here is position on the drug type axis reported above. One line leads on both counts here: Generic holds 90% of 2025 revenue and compounds fastest at 5.2%. The commercial size of that position is USD 0.492 billion in 2025, moving to USD 0.869 billion by 2034 across the forecast period.

6.5% of global revenue is generated in Japan; USD 0.123 billion in 2025, reaching USD 0.217 billion in 2034, and 25% of Asia Pacific.

India is sized at USD 0.098 billion in 2025, rising to USD 0.174 billion by 2034; 5.2% of global revenue and 19.9% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.

USD 0.133 billion of 2025 revenue is generated in Latin America, 7% of the global mirtazapine drug market with USD 0.232 billion projected for 2034. That makes it the fourth-largest region covered, in 2025 and again in 2034.

Its share rises to 8% over the forecast period, on growth above the market's own 4.85%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

The drug type mix reported at global level applies here, with Generic the largest line at 90% of 2025 revenue and Generic the fastest-growing at 5.2%. Per-axis and per-country detail for Latin America sits in the full report.

The largest single market in Latin America is Brazil, at USD 0.073 billion in 2025 and USD 0.128 billion in 2034. 54.9% of the region in the base year makes it the largest market here without making it the region. The region itself runs USD 0.133 billion to USD 0.232 billion over the same period, and this is the market carrying the country-level detail in the full report.

Brazil buys along the same lines as the market globally; Generic first at 90% of 2025 revenue and 92.7% in 2034, Generic fastest at 5.2% on a share moving from 90% to 92.7%. With 54.9% of Latin America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The full report reports Brazil by drug type separately.

In Brazil, mirtazapine is regulated by Agência Nacional de Vigilância Sanitária, the national health surveillance agency responsible for drug registration and market authorization. Because mirtazapine acts on the central nervous system, it is subject to the special control rules that Brazil applies to psychotropic medicines, meaning it can be dispensed only against a retained prescription and its movement through the supply chain is tracked separately from ordinary pharmaceuticals. A supplier must register the product with Anvisa, demonstrate conformity with Brazilian Good Manufacturing Practice standards, and use labelling and package inserts approved in Portuguese. Post-approval, the registration holder must maintain pharmacovigilance reporting to the agency for as long as the product remains on the market.

Supplier positions in Brazil sit on the drug type axis: the country buys the same lines the global market does, in the same order. Generic is where the volume is, at 90% of 2025 revenue, and it is growing fastest as well at 5.2%. A supplier weighted toward Latin America is competing over a base of USD 0.133 billion in 2025 reaching USD 0.232 billion by 2034, 7% of global revenue at the start of that period.

Within Latin America, Mexico accounts for 35.3% of regional revenue and 2.5% of the global total, worth USD 0.047 billion in 2025 and USD 0.081 billion by 2034.

USD 0.095 billion of 2025 revenue is generated in Middle East and Africa, 5% of the global mirtazapine drug market with USD 0.145 billion projected for 2034. By revenue it sits fifth across the study, and the ranking does not change between 2025 and 2034.

By 2034 the share stands at 5%, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.

Segment composition follows the global pattern: Generic largest at 90% of 2025 revenue, Generic fastest at 5.2%. Middle East and Africa is reported axis by axis and country by country in the full study.

40% of Middle East and Africa's base-year revenue comes from Saudi Arabia; USD 0.038 billion, rising to USD 0.058 billion by 2034. 40% of the region in the base year makes it the largest market here without making it the region. Regional revenue of USD 0.095 billion in 2025 and USD 0.145 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

The drug type pattern in Saudi Arabia is the global one: 90% of 2025 revenue in Generic, 92.7% by 2034, against 5.2% growth in Generic taking it from 90% to 92.7%. Because the country carries 40% of Middle East and Africa, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Saudi Arabia carries its own drug type breakdown in the full report.

In Saudi Arabia, mirtazapine is regulated by the Saudi Food and Drug Authority, which controls the registration, import, and distribution of pharmaceutical products across the Kingdom. A supplier must obtain marketing authorization before the product can be sold, submitting quality, safety, and efficacy data that the Authority reviews against Gulf Cooperation Council harmonized technical requirements. Manufacturing sites, whether local or overseas, must hold Good Manufacturing Practice certification recognized by the Authority, and Arabic-language labelling meeting the Authority's pharmaceutical labelling guidelines must accompany every package. Since mirtazapine is dispensed only against a physician's prescription, pharmacies must retain prescription records, and the marketing authorization holder is responsible for ongoing pharmacovigilance reporting to the Authority.

Competition in Saudi Arabia is decided on the drug type axis rather than on geography, since suppliers here sell into the same drug type lines reported globally. Generic is both the largest line, at 90% of 2025 revenue, and the fastest-growing at 5.2%. The commercial size of that position is USD 0.095 billion in 2025 and USD 0.145 billion by 2034, 5% of the global total in the base year.

1.5% of global revenue is generated in South Africa; USD 0.029 billion in 2025, reaching USD 0.044 billion in 2034, and 30.5% of Middle East and Africa.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Drug Type, Dosage Form, Application, Distribution Channel, End User, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.